Table 1.

Ongoing clinical trials with PRRT.

Study Title	Study NCT Number	Phase	Treatment	Patient population
Lu-177 DOTATATE (Lutathera) in Combination with Olaparib in Inoperable Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)	NCT04086485	I/II	Lu-177 DOTATATE + Olaparib	Inoperable or metastatic GEP-NETs
Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases	NCT03457948	II	Lu-177 DOTATATE or liver-directed therapies + Pembrolizumab	G1-G3 NETs
Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer	NCT04194125	II	Y-90 DOTATOC + CAPTEM	G1-G2 GEP-NETs
Peptide Receptor Radionuclide Therapy (PRRT) in Tumors with High Expression of Somatostatin Receptors (Phase 2) (FENET-2016)	NCT04790708	II	Lu-177 DOTATOC ± Y-90 DOTATOC (monotherapy arms and combination arms; retreatment arms of individual therapy)	GEP-NETs, Bronchial NETs, Pheochromocytoma, Paraganglioma, Neuroblastoma, other NETs (skin, thyroid, parathyroid origin), NETs of unknown primary
Targeted Alpha-emitter Therapy of PRRT Naive Neuroendocrine Tumor Patients (ALPHAMEDIX02)	NCT05153772	II	Pb-212 DOTAMTATE	NENs
Intra-arterial Hepatic (IAH) Infusion of Radiolabeled Somatostatin Analogs in GEP-NET Patients With Dominant Liver Metastases (LUTARTERIAL)	NCT04837885	II	Lu-177 DOTATATE via intrahepatic injection	GEP-NETs
Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled with Terbium-161 (Tb-161 DOTA-LM3) (Beta plus)	NCT05359146	I	Lu-177 DOTATOC and Tb-161 DOTA-LM3	GEP-NENs (G1 and G2 only)